Seattle, United States
RareCyte, Inc. is a prominent player in the field of Spatial Biology and Liquid Biopsy solutions, offering a comprehensive range of services to leaders across Research, Translational Medicine, and the Clinic. Headquartered in Seattle, WA, the company has been at the forefront of developing innovative technologies and end-to-end integrated platforms since its establishment in 2009.
Their highly multiplexed fluorescent imaging systems, reagents, and contract services have been instrumental in advancing various sectors including oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. RareCyte's focus on empowering investigators to unlock spatial context for key biomarkers has been pivotal in the development of therapeutics and companion diagnostics through rare cell analysis.
The latest investment for RareCyte, Inc. comes in the form of a grant investment at 03 November 2022, with the Gastro-Intestinal Research Foundation being the contributing investors. With its strong presence in the Biotechnology and Health Care industries, RareCyte continues to drive innovation and make significant strides in the field of precision biology.
